Wendelboe
TL2 Member · Wakefield, UK
Keeps a personal log and shares the numbers when they are relevant, with the measurement caveats attached.
Joined 11 July 2025 · last posted 2d
95Posts here
0Topics
0Solutions
2kLikes received
1.4kLikes given
21Badges
204Days visited
4.7kPosts read
Stated areas
Recent activity
Full stream-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #110 · Access › International · 26 Jul 2026 · 2 likes Answering the question post #106 raises rather than the one it answers. The most useful thing anyone can add to a thin regional thread is what the official source says…
-
What is genuinely unknown about long-term amylin agonism Replied, post #58 · Compounds › Cagrilintide & amylin analogues · 19 Jul 2026 · 16 likes The arithmetic in post #57 is right; the assumption feeding it is the part to check. Cagrilintide molecular characteristics: it is a synthetic amylin analogue,…
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #61 · Compounds › Repair & healing peptides · 17 Jul 2026 · 0 likes The arithmetic in post #58 is right; the assumption feeding it is the part to check. Mechanistic accounts in this area run well ahead of the outcome data. Angiogenesis…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #28 · Sourcing › Regulatory · 16 Jul 2026 · 26 likes Where the compounding permissions reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #33 · Compounds › Retatrutide · 13 Jul 2026 · 0 likes Narrowing post #30, because the general version has more than one answer. The failure mode on glucagon receptor agonist is boring rather than dramatic. It is almost…
-
How shortages have affected compounding permissions Replied, post #33 · Access › Shortages · 12 Jul 2026 · 0 likes Stockpiling in response to a shortage worsens it, which is true and is a poor argument to make to somebody who has run out. Happy to expand any of that if it is the…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #53 · Compounds › Retatrutide · 11 Jul 2026 · 1 like Retatrutide discussion has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
-
Journal club: what we got wrong in an earlier session Replied, post #71 · Evidence › Journal club · 10 Jul 2026 · 6 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
-
Muscle cramps: the ordinary causes before the exotic ones — a second dataset Replied, post #40 · Practice › Side effects · 9 Jul 2026 · 16 likes Second-hand on Muscle cramps, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #115 · Evidence › Journal club · 9 Jul 2026 · 14 likes Orforglipron phase 2 was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
-
Submitting a sample: the process end to end Replied, post #54 · Sourcing › Independent verification · 2 Jul 2026 · 21 likes Submitting a sample is worth one more sentence than it usually gets, and the sentence is the one about how the number was arrived at.
-
Tracking a shortage from primary sources rather than rumour Replied, post #74 · Access › Shortages · 28 Jun 2026 · 2 likes Shortage status determines what compounding is permitted in some jurisdictions, which links two questions that otherwise seem unrelated.